Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury.
The widespread introduction of fibrinolytics and recently also PTCA in the treatment of myocardial infarction has changed the picture of modern cardiology. But this therapy also raises new problems and challenges. One of them is the occurrence of extensive tissue injury caused by reperfusion. Reinstitution of oxygen to the ischemic tissues initiates various processes leading to generation of reactive oxygen species (ROSs). Acting on the plasma membrane ROS damage its organization and release various proinflammatory agents. Different proteins, including receptors, ionic channels, transporters or components of transduction pathways are substrates of oxidation by ROSs. Their changed structure results in altered functioning and disruption of vital cellular processes. Another key factor of reperfusion injury is activation and infiltration of infarcted area by polymorphonuclear leukocytes (PMNs). Multiple studies identified consecutive stages of PMN activation and substances being involved in it. Main interest lies in cellular adhesion molecules, particularly selectins and beta2 integrins, as their antagonists were repeatedly found to diminish neutrophil activation and infarct size. Nevertheless new publications strike at the foundations of the established order and confront the relation between neutrophil infiltration and infarct size. PMNs are linked by close ties to other cells involved in inflammatory response. Seemingly also in cardiac ischemia-reperfusion injury, the activity of neutrophils is modulated by lymphocytes and macrophages. The article describes mutual interactions between different factors involved in the reperfusion injury that may enable preparing new treatments, hopefully as effective and successful as reperfusion therapy.
Kaminski
Karol A
KA
Department of Cardiology, Medical Academy of Bialystok, ul. M. Sklodowskiej-Curie 24a, Bialystok, Poland.
Bonda
Tomasz A
TA
Korecki
Janusz
J
Musial
Wlodzimierz J
WJ
D000818:Animals; D016207:Cytokines / Q000502:physiology; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000502:physiology; D008264:Macrophages / Q000502:physiology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D018375:Neutrophil Activation / Q000187:drug effects / Q000502:physiology*; D018384:Oxidative Stress / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000502:physiology
D016207:Cytokines; D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase